Alger Associates, Inc. Acquires 10.2% Stake in Forte Biosciences, Inc. (FBRX)

Alger Associates, Inc. has filed a Schedule 13G/A (Amendment No. 8) regarding its holdings in Forte Biosciences, Inc. (FBRX). As of the event date on March 31, 2026, the filer reported beneficial ownership of 1,272,596 shares of common stock, representing a 10.2% stake in the company. This marks a significant increase from the previously reported 0.0% ownership position, indicating a new substantial holding by the firm. The shares are held through its subsidiaries, including Fred Alger Management, LLC (FAM), which acts as an investment adviser to various open-end investment companies and managed accounts. Alger Associates, Inc. serves as the ultimate parent holding company. The filing was made under Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The filing was signed by Hal Liebes, Secretary of Alger Associates, Inc., on May 15, 2026.